AgomAb Therapeutics NV (AGMB)

NASDAQ: AGMB · Real-Time Price · USD

8.84

+0.15 (1.73%)

Oct 6, 2026, 4:00 PM EDT - Market closed

AgomAb Therapeutics NV Earnings Call Transcripts

Fiscal Year 2026

Study result
The STENOVA phase IIa open-label extension showed ontunisertib maintained a favorable safety profile and gut-restricted pharmacokinetics over 60 weeks in fibrosing Crohn's disease. The annualized event rate was only 3%, with significant improvements in symptoms and quality of life, supporting further development in larger, controlled trials.

Read full transcript →

Press release
Slides